Skip to main content
SpringerLink
Log in

Cardiomyopathy in tyrosinaemia type I is common but usually benign

  • Original Article
  • Published:
Journal of Inherited Metabolic Disease

Summary

Tyrosinaemia type I (TTI) is an inherited multisystemic disorder of tyrosine metabolism. In addition to hepatic and renal involvement, cardiomyopathy is an important clinical manifestation. Objective: To evaluate the incidence and outcome of cardiomyopathy in TTI. Subjects and methods: A retrospective study was performed of 20 consecutive children with TTI (12 male, 8 female) referred to a single centre between 1986 and 2002. All were initially treated with standard dietary therapy and, since 1992, with nitisinone. The indications for orthotopic liver transplantation (LT) changed during the study. Serial echocardiography was undertaken in all subjects. Results: 9/20 (45%) children had an acute hepatic presentation. Five (25%) received dietary treatment followed by LT, and 14 (70%) were treated with nitisinone at presentation. 6/20 (30%) had cardiomyopathy at initial assessment, with interventricular septal hypertrophy being the commonest finding (5/6). Cardiomyopathy was significantly less common in those treated initially with nitisinone. After a median follow-up of 3.6 (0.45–13.5) years, 5/6 (83%) had complete resolution of cardiomyopathy and 1/6 showed significant improvement. No child with a normal initial echocardiography subsequently developed cardiomyopathy. Conclusion: Cardiomyopathy is a common manifestation of TTI and it has a favourable long-term outcome. Children initially treated with nitisinone are less likely to develop this complication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anan R, Nakagawa M, Miyata M, et al (1995) Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91: 955–961.

    CAS  PubMed  Google Scholar 

  • Andre N, Roquelaure B, Jubin V, Ovaert C (2005) Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I. J Inherit Metab Dis 28: 103–106.

    CAS  PubMed  Google Scholar 

  • Berger R, van Faassen H, Taanman JW, De Vries H, Agsteribbe E (1987) Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. Pediatr Res 22: 394–398.

    CAS  PubMed  Google Scholar 

  • Berko BA, Swift M (1987) X-linked dilated cardiomyopathy. N Engl J Med 316: 1186–1191.

    CAS  PubMed  Google Scholar 

  • Briggs DW, Condie LW, Sedman RM, Tephly TR (1976) δ-Aminolevulinic acid synthetase in the heart. J Biol Chem 251: 4996–5001.

    CAS  PubMed  Google Scholar 

  • Edwards MA, Green A, Colli A, Rylance G (1987) Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy. Lancet 1: 1437–1438.

    CAS  PubMed  Google Scholar 

  • Forget S, Patriquin HB, Dubois J, et al (1999) The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 29: 104–108.

    Article  CAS  PubMed  Google Scholar 

  • Franz WM, Muller OJ, Katus HA (2001) Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358: 1627–1637.

    Article  CAS  PubMed  Google Scholar 

  • Graber HL, Unverferth DV, Baker PB, Ryan JM, Baba N, Wooley CF (1986) Evolution of a hereditary cardiac conduction and muscle disorder: a study involving a family with six generations affected. Circulation 74: 21–35.

    CAS  PubMed  Google Scholar 

  • Gross DM, Williams JC, Caprioli C, Dominguez B, Howell RR (1988) Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 61: 170–176.

    Article  CAS  PubMed  Google Scholar 

  • Heath SK, Gray RG, McKiernan P, Au KM, Walker E, Green A (2002) Mutation screening for tyrosinaemia type I. J Inherit Metab Dis 25: 523–524.

    Article  CAS  PubMed  Google Scholar 

  • Herman MA, Webber J, Fromm D, Kessel D (1998) Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol B 43: 61–65.

    Article  CAS  PubMed  Google Scholar 

  • Holme E, Lindstedt S (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21: 507–517.

    CAS  PubMed  Google Scholar 

  • Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4: 805–814.

    Article  CAS  PubMed  Google Scholar 

  • Jain D (2005) Cardiovascular involvement in patients with liver cirrhosis. J Hepatol 42: 3–4.

    Article  PubMed  Google Scholar 

  • Kappas A, Sassa S, Galbraith RA, Nordmann Y (1995) The porphyrias. In: Scriver CR, Beaudet AL, Slyws, Valled, eds. The Metabolic and Molecular Basics of Inherited Disease, 7th edn. New York: McGraw-Hill, 1305–1322.

  • Kordac V, Kozakova M, Martasek P (1989) Changes of myocardial functions in acute hepatic porphyrias. Role of heme arginate administration. Ann Med 21: 273–276.

    CAS  PubMed  Google Scholar 

  • Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74: 4641–4645.

    Google Scholar 

  • Lindblad B, Fallstrom SP, Hoyer S, Nordborg C, Solymar L, Velander H (1987) Cardiomyopathy in fumarylacetoacetase deficiency (hereditary tyrosinaemia): a new feature of the disease. J Inherit.Metab Dis 10: 319–322.

    Article  Google Scholar 

  • Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813–817.

    Article  CAS  PubMed  Google Scholar 

  • Mestroni L, Miani D, Di Lenarda A, et al (1990) Clinical and pathologic study of familial dilated cardiomyopathy. Am J Cardiol 65: 1449–1453.

    Article  CAS  PubMed  Google Scholar 

  • Miller CG, Alleyne GA, Brooks SE (1972) Gross cardiac involvement in glycogen storage disease type 3. Br Heart J 34: 862–864.

    CAS  PubMed  Google Scholar 

  • Mohan N, McKiernan P, Preece MA, et al (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158 (Supplement 2): S49–S54.

    PubMed  Google Scholar 

  • Moller S, Henriksen JH (2002) Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 87: 9–15.

    Article  CAS  PubMed  Google Scholar 

  • Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM (1998) Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab 64: 119–125.

    Article  CAS  PubMed  Google Scholar 

  • Richardson P, McKenna W, Bristow M, et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93: 841–842.

    Google Scholar 

  • Russo PA, Mitchell GA, Tanguay RM (2001) Tyrosinemia: a review. Pediatr.Dev.Pathol. 4: 212–221.

    Article  CAS  PubMed  Google Scholar 

  • Sedman R, Ingall G, Rios G, Tephly TR (1982) Heme biosynthesis in the heart. Biochem Pharmacol 31: 761–766.

    CAS  PubMed  Google Scholar 

  • Torregrosa M, Aguade S, Dos L, et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42: 68–74.

    Article  PubMed  Google Scholar 

  • van Spronsen FJ, Thomasse Y, Smit GP, et al (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20: 1187–1191.

    Article  CAS  PubMed  Google Scholar 

  • Weinberg AG, Mize CE, Worthen HG (1976) The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 88: 434–438.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Department of Cardiology, Children’s Hospital NHS Trust, Birmingham, UK

    N. Arora, O. Stumper, J. Wright, D. A. Kelly & P. J. McKiernan

Authors
  1. N. Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Stumper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. A. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. J. McKiernan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. McKiernan.

Additional information

Communicating editor: Georg Hoffmann

Competing interests: None declared

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arora, N., Stumper, O., Wright, J. et al. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 29, 54–57 (2006). https://doi.org/10.1007/s10545-006-0203-5

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-006-0203-5

Keywords

Search

Navigation